IGC Pharma (NYSEMKT:IGC) Given New $3.75 Price Target at Ascendiant Capital Markets

IGC Pharma (NYSEMKT:IGC) had its price target hoisted by Ascendiant Capital Markets from $3.50 to $3.75 in a research report report published on Tuesday morning, Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.

IGC Pharma Trading Down 3.1 %

Shares of NYSEMKT:IGC opened at $0.35 on Tuesday. The stock has a market cap of $26.37 million, a P/E ratio of -1.58 and a beta of 1.30. The company has a current ratio of 1.77, a quick ratio of 1.16 and a debt-to-equity ratio of 0.02.

About IGC Pharma

IGC Pharma, Inc, a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer’s disease. The company’s lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer’s; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development.